rfxcel will be at the Healthcare Distribution Alliance’s (HDA’s) 2019 Traceability Seminar October 21-23 at the Marriott Wardman Park Hotel in Washington, D.C. Stop by Booth 9 to meet our team and learn the latest from the industry’s leader in supply chain track and trace solutions!
The annual Traceability Seminar brings together healthcare supply chain leaders to learn more about implementation milestones of the Drug Supply Chain Security Act (DSCSA) — as well as innovative approaches and lessons learned — as distributors, manufacturers, and dispensers implement serialization and traceability technologies to further preserve the safety and security of the healthcare supply chain.
Get the Latest News about the DSCSA VRS
We’re looking forward to hosting a discussion about the state of the Verification Router Service (VRS)!
As you probably know, rfxcel is leading the U.S. Food and Drug Administration’s (FDA’s) pilot to measure readiness for the VRS. We’ll share the interim pilot report we’ve prepared for the FDA, which presents findings of the tests we’ve conducted across the VRS network of providers.
We began our VRS pilot in June. It’s designed to quantify the readiness of the VRS network to meet the DSCSA’s Saleable Returns Verification Requirement. The pilot builds on the HDA’s VRS efforts and will systematically verify, measure, and report on the ability of the VRS network to meet the functional requirements of VRS.
A key and unique aspect of the pilot is that we have been sharing the details of our VRS test cases with all VRS providers to ensure they have a common detailed set of test cases. We’ll continue to work with the providers to verify the test conditions to enable maximum readiness of the VRS network across all VRS providers.
Hear What the Extension of the DSCSA Saleable Returns Verification Requirement Means for Your Business
This year’s Traceability Seminar comes less than a month after the FDA announced that it did “not intend to take action against wholesale distributors” that do not meet the DSCSA Saleable Returns Verification Requirement before November 27, 2020. This is a 1-year extension of the original deadline for wholesale distributors to verify a product identifier before further distributing a returned product. (Read our recap of the FDA announcement here.)
As the pharma industry’s thought leader on VRS, rfxcel is ready to talk about this development. Based on what we’ve learned from our VRS pilot, we believe the FDA made the right decision because it will allow the industry to test more production-like scenarios.
No matter what, companies should continue with their planned VRS implementation efforts so they’ll benefit from the continued testing. Companies that wait will not benefit from the extended test cycles and (like previous delays in enforcement) will end up competing for limited resources when the new deadline approaches.
Be sure to ask us questions and get copy of our interim report so you can navigate the DSCSA over the coming months.
A Final Thought: Trust rfxcel to Ensure You’re DSCSA-Compliant
Book an appointment now or just come to Booth 9 at the Traceability Seminar to see how our VRS pilot is measuring and ensuring the seamless interoperability between VRS providers across a broad range of use cases. rfxcel is the longest-tenured track and trace solution provider in the pharma industry and is leading the way on the VRS. We’re ready to share our expertise!
The FDA extension doesn’t change the fact that complete and consistent verification of the VRS use cases is critical to successfully meeting the DSCSA Saleable Returns Verification Requirement. Companies should remain on course and use the extra time to ensure they’re ready for 2020. rfxcel’s team of experts and our leading-edge trace and trace solutions are all you need to ensure you’re always compliant.
